By combining Patheon’s capabilities in drug development and manufacturing with its clinical trials packaging and logistics expertise, Thermo Fisher will be able to provide an end-to-end solution for its biopharma customers. Dr John Rontree, Senior Director of Marketing, Pharmaceuticals and Biopharmaceuticals, Thermo Fisher Scientific, discusses his company’s plans.
What do you see as the changes which have had the biggest impact on the market over the past 21 years and how has Thermo Fisher met them?
The most significant change has been the shift from the development of small, more broadly acting molecules to large, complex biologics which act with high specificity and potency. From an analytical perspective, in every pharma company 20 years ago there was what was known as a core services laboratory. Today we see more of an at-source demand where bioanalysts are focused on getting answers faster, and on transforming high numbers of samples into immediate, meaningful, knowledge. Over this period, we have risen to the challenge of providing solutions to unravel the increasing complexity of biologics – and we continue to work on the simplification of these powerful technologies.
Are you looking to explore how lipid formulations in softgels can enhance drug absorption and bioavailability. Register for our upcoming webinar to find out!
3 September 2025 | 3:00 PM BST | FREE Webinar
This webinar will delve into the different types of lipid formulations, such as solutions, suspensions, emulsions, and self-(micro)emulsifying systems. Applications span diverse therapeutic areas including HIV therapy, oncology, immunosuppressants, and emerging treatments like medicinal cannabis (eg, CBD).
What You’ll Learn:
Lipid formulation development and screening tools for optimisation
Key steps in scale-up and industrialisation to ensure consistency and efficiency
Impact of lipid-based softgels on drug delivery and patient outcomes.
Can’t attend live? No worries – register to receive the recording post-event.
Most recently, we have seen a huge change in bioproduction strategies and in manufacturing as a whole, where analytical technologies – once reserved for offline analysis by chemistries, manufacturing and control (CMC) groups – are being implemented in an online production environment.
[insert_php] if ( zmember_valid_subscription() ) { echo ‘
DOWNLOAD THE ENTIRE 21st ANNIVERSARY SUPPLEMENT NOW
Our 21 @ 21 Anniversary Supplement is just one of the many resources a free subscription to European Pharmaceutical Review provides. If you are already a subscriber, login to download the PDF.
Not yet a subscriber? Join our growing community of thousands of industry professionals and gain access to:
Bi-monthly issues in print and/or digital format
Case studies, whitepapers, webinars and industry-leading content
Breaking news and features
Our extensive online archive of over 8,500 articles and past issues
Growth in the Asia-Pacific market has also been significant – today comprising almost 40% of our overall business for chromatography and mass spectrometry. Such growth is driven by increased biosimilar manufacturing, alongside a significant existing generic pharmaceutical market. To best serve the expanding eastern pharma market, we continue to build and adapt our teams in these regions.
Thermo Fisher Scientific has grown over the years, with a stream of acquisitions across various life science sectors and product categories. With the purchase of Patheon, has the relationship between equipment suppliers and CMO/CDMOs changed, and do you see the potential for more mergers?
By combining Patheon’s capabilities in drug development and manufacturing with our clinical trials packaging and logistics expertise, we will be able to provide an end-to-end solution for our biopharma customers – from initial drug formulation to clinical trials support, to commercial production.
There are huge opportunities for us to collaboratively develop differentiated workflows, products and services. We hope to be able to consider pharmaceutical manufacture more holistically; streamlining work streams, creating a greater return on investment for our customers and significantly reducing the time-to-market for new drugs, potentially saving lives that could have been lost while waiting.
Many small-medium biotech sponsors who outsource to Patheon are looking for one-stop-shop solutions providers. It has recently been shown that great efficiencies can be gained for sponsors who employ single-source outsourcing partners, versus a multivendor development Dr John Rontree, Senior Director of Marketing, Pharmaceuticals and Biopharmaceuticals, Thermo Fisher Scientific and manufacturing model.1 Thermo Fisher Scientific is uniquely positioned to provide these solutions and services due to the breadth of our portfolio.
Looking ahead to the next few years, what do you think are likely to be the main opportunities and challenges affecting the industry and how is Thermo Fisher geared up to meet them?
I believe one of the biggest changes to come will be seen in quality assurance/ quality control (QA/QC). There is a huge shift towards the implementation of singleuse biotechnologies, continuous (leaner) manufacturing outfits and the need for advanced process analytical technologies (PAT) for ‘real time lot release’.
As a company, we already provide the tools and solutions to address many of these changes. One specific example that comes to mind is the application of ultrahigh performance liquid chromatography (UHPLC) and high resolution accurate mass (HRAM) mass spectrometry (MS) in the late drug development, manufacturing, formulation and QA/QC environment. This is an area in which we are pioneers. The so-called ‘multi-attribute method’ (MAM) has been directly driven by the biopharma industry and is being developed and adopted at an unprecedented pace. There is certainly a growing pressure to make highend analytical technologies more portable, simpler to use and smaller in size to better fit within the manufacturing environment.
Another challenge this raises is the need for more ‘global’ workflows and ‘platform technologies’ that can easily be re-purposed from one drug molecule to the next. A significant amount of time, money and resource is spent in the area of method development. We are partnering with the National Institute of Bioprocessing Research and Training (NIBRT) in Dublin, Ireland, to address this particular bottleneck – to bring fit-for-purpose, freely available methodologies which are applicable to a range of monoclonal antibody-based therapies, directly to our customers.
Longer term, how do you see the future for the sector and what is the role of companies such as Thermo Fisher in creating that future?
The ability to share, manage and unlock the knowledge in big data is a major opportunity for the pharmaceutical sector. Our goals are well aligned with this – and the opportunities presented by cloud-based strategies. Our ambition is to become the leading digital science company, through expansion and development of our digital capabilities. Digital has the potential to change the way our customers work – providing them with unmatched capabilities for commerce, services and innovation, so driving productivity and ultimately power science. We have already created a ‘digital transformation office’ that will provide strategic alignment to connect our digital offerings into a common platform and we will form strategic partnerships to help strengthen our digital offerings.
If there was one thing you could change within the sector, knowing what has happened in the past 21 years, what would it be?
I personally believe that we could, as an industry, be more collaborative. Notwithstanding the challenges of intellectual property (IP), there are so many opportunities to advance the analytical tools and strategies to the benefit of the life science industry as a whole. We are now starting to see exciting strategic partnerships form, focused on the creation of solutions to problems that no one company alone could tackle. Examples include the Emerging Technologies Consortium (ETC), the BioPhorum Operations Group (BPOG) and the recently announced Partnership for Accelerating Cancer Therapies (PACT) from the National Institutes of Health (NIH).
Such initiatives bring both the big pharma companies and ourselves as instrumentation vendors/solutions providers together, to work through specific problems and industry challenges. Such collaborations will facilitate the provision of superior, next-generation, solutions for the pharma industry, and ultimately better medicines, faster.
This website uses cookies to enable, optimise and analyse site operations, as well as to provide personalised content and allow you to connect to social media. By clicking "I agree" you consent to the use of cookies for non-essential functions and the related processing of personal data. You can adjust your cookie and associated data processing preferences at any time via our "Cookie Settings". Please view our Cookie Policy to learn more about the use of cookies on our website.
This website uses cookies to improve your experience while you navigate through the website. Out of these cookies, the cookies that are categorised as ”Necessary” are stored on your browser as they are as essential for the working of basic functionalities of the website. For our other types of cookies “Advertising & Targeting”, “Analytics” and “Performance”, these help us analyse and understand how you use this website. These cookies will be stored in your browser only with your consent. You also have the option to opt-out of these different types of cookies. But opting out of some of these cookies may have an effect on your browsing experience. You can adjust the available sliders to ‘Enabled’ or ‘Disabled’, then click ‘Save and Accept’. View our Cookie Policy page.
Necessary cookies are absolutely essential for the website to function properly. This category only includes cookies that ensures basic functionalities and security features of the website. These cookies do not store any personal information.
Cookie
Description
cookielawinfo-checkbox-advertising-targeting
The cookie is set by GDPR cookie consent to record the user consent for the cookies in the category "Advertising & Targeting".
cookielawinfo-checkbox-analytics
This cookie is set by GDPR Cookie Consent WordPress Plugin. The cookie is used to remember the user consent for the cookies under the category "Analytics".
cookielawinfo-checkbox-necessary
This cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Necessary".
cookielawinfo-checkbox-performance
This cookie is set by GDPR Cookie Consent WordPress Plugin. The cookie is used to remember the user consent for the cookies under the category "Performance".
PHPSESSID
This cookie is native to PHP applications. The cookie is used to store and identify a users' unique session ID for the purpose of managing user session on the website. The cookie is a session cookies and is deleted when all the browser windows are closed.
viewed_cookie_policy
The cookie is set by the GDPR Cookie Consent plugin and is used to store whether or not user has consented to the use of cookies. It does not store any personal data.
zmember_logged
This session cookie is served by our membership/subscription system and controls whether you are able to see content which is only available to logged in users.
Performance cookies are includes cookies that deliver enhanced functionalities of the website, such as caching. These cookies do not store any personal information.
Cookie
Description
cf_ob_info
This cookie is set by Cloudflare content delivery network and, in conjunction with the cookie 'cf_use_ob', is used to determine whether it should continue serving “Always Online” until the cookie expires.
cf_use_ob
This cookie is set by Cloudflare content delivery network and is used to determine whether it should continue serving “Always Online” until the cookie expires.
free_subscription_only
This session cookie is served by our membership/subscription system and controls which types of content you are able to access.
ls_smartpush
This cookie is set by Litespeed Server and allows the server to store settings to help improve performance of the site.
one_signal_sdk_db
This cookie is set by OneSignal push notifications and is used for storing user preferences in connection with their notification permission status.
YSC
This cookie is set by Youtube and is used to track the views of embedded videos.
Analytics cookies collect information about your use of the content, and in combination with previously collected information, are used to measure, understand, and report on your usage of this website.
Cookie
Description
bcookie
This cookie is set by LinkedIn. The purpose of the cookie is to enable LinkedIn functionalities on the page.
GPS
This cookie is set by YouTube and registers a unique ID for tracking users based on their geographical location
lang
This cookie is set by LinkedIn and is used to store the language preferences of a user to serve up content in that stored language the next time user visit the website.
lidc
This cookie is set by LinkedIn and used for routing.
lissc
This cookie is set by LinkedIn share Buttons and ad tags.
vuid
We embed videos from our official Vimeo channel. When you press play, Vimeo will drop third party cookies to enable the video to play and to see how long a viewer has watched the video. This cookie does not track individuals.
wow.anonymousId
This cookie is set by Spotler and tracks an anonymous visitor ID.
wow.schedule
This cookie is set by Spotler and enables it to track the Load Balance Session Queue.
wow.session
This cookie is set by Spotler to track the Internet Information Services (IIS) session state.
wow.utmvalues
This cookie is set by Spotler and stores the UTM values for the session. UTM values are specific text strings that are appended to URLs that allow Communigator to track the URLs and the UTM values when they get clicked on.
_ga
This cookie is set by Google Analytics and is used to calculate visitor, session, campaign data and keep track of site usage for the site's analytics report. It stores information anonymously and assign a randomly generated number to identify unique visitors.
_gat
This cookies is set by Google Universal Analytics to throttle the request rate to limit the collection of data on high traffic sites.
_gid
This cookie is set by Google Analytics and is used to store information of how visitors use a website and helps in creating an analytics report of how the website is doing. The data collected including the number visitors, the source where they have come from, and the pages visited in an anonymous form.
Advertising and targeting cookies help us provide our visitors with relevant ads and marketing campaigns.
Cookie
Description
advanced_ads_browser_width
This cookie is set by Advanced Ads and measures the browser width.
advanced_ads_page_impressions
This cookie is set by Advanced Ads and measures the number of previous page impressions.
advanced_ads_pro_server_info
This cookie is set by Advanced Ads and sets geo-location, user role and user capabilities. It is used by cache busting in Advanced Ads Pro when the appropriate visitor conditions are used.
advanced_ads_pro_visitor_referrer
This cookie is set by Advanced Ads and sets the referrer URL.
bscookie
This cookie is a browser ID cookie set by LinkedIn share Buttons and ad tags.
IDE
This cookie is set by Google DoubleClick and stores information about how the user uses the website and any other advertisement before visiting the website. This is used to present users with ads that are relevant to them according to the user profile.
li_sugr
This cookie is set by LinkedIn and is used for tracking.
UserMatchHistory
This cookie is set by Linkedin and is used to track visitors on multiple websites, in order to present relevant advertisement based on the visitor's preferences.
VISITOR_INFO1_LIVE
This cookie is set by YouTube. Used to track the information of the embedded YouTube videos on a website.